Cancer treatment reviews, 2017-01, Vol.52, p.12-21
2017
Volltextzugriff (PDF)
Details
- Autor(en) / Beteiligte
- Titel
- Factors associated with failure of oncology drugs in late-stage clinical development: A systematic review
- Ist Teil von
- Cancer treatment reviews, 2017-01, Vol.52, p.12-21
- Ort / Verlag
- Netherlands: Elsevier Ltd
- Erscheinungsjahr
- 2017
- Quelle
- MEDLINE
- Beschreibungen/Notizen
- Highlights • Drug development in oncology is characterized by a high rate of failure at the stage of phase III trials. • Achieving proof of concept based on drug activity after a phase II trial increases the likelihood of later approval. • Drugs developed under a biomarker-based selection strategy are less likely to fail at late stages of development.
- Sprache
- Englisch
- Identifikatoren
- ISSN: 0305-7372eISSN: 1532-1967DOI: 10.1016/j.ctrv.2016.10.009Titel-ID: cdi_proquest_miscellaneous_1844027506
- Format
- –
- Schlagworte
- Antineoplastic Agents - therapeutic use, Biomarker, Clinical Trials, Phase II as Topic, Clinical Trials, Phase III as Topic, Drug development, Drug Evaluation - methods, Drug Evaluation - standards, FDA, Hematology, Oncology and Palliative Medicine, Humans, Neoplasms - drug therapy, Phase III trials, Precision medicine, Randomized Controlled Trials as Topic, United States, United States Food and Drug Administration